FDA Approves JANUMET — Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC announced the FDA approval of JANUMET (sitagliptin and metformin hydrochloride) for the oral treatment of type 2 diabetes on March 30, 2007, to mitigate market competition for the dominant branded Metformin segment and counteract generic erosion.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed